<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Simcere Pharmaceutical Group Ltd — News on 6ix</title>
    <link>https://6ix.com/company/simcere-pharmaceutical-group-ltd</link>
    <description>Latest news and press releases for Simcere Pharmaceutical Group Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 27 Jan 2026 10:40:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/simcere-pharmaceutical-group-ltd" rel="self" type="application/rss+xml" />
    <item>
      <title>Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease</title>
      <link>https://6ix.com/company/simcere-pharmaceutical-group-ltd/news/boehringer-ingelheim-simcere-partner-advance-104000563</link>
      <guid isPermaLink="true">https://6ix.com/company/simcere-pharmaceutical-group-ltd/news/boehringer-ingelheim-simcere-partner-advance-104000563</guid>
      <pubDate>Tue, 27 Jan 2026 10:40:00 GMT</pubDate>
      <description>Simcere Pharmaceutical Group Ltd. (&quot;Simcere&quot;) (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).</description>
    </item>
    <item>
      <title>Simcere&apos;s IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage</title>
      <link>https://6ix.com/company/simcere-pharmaceutical-group-ltd/news/simceres-il-2-mutant-fusion-protein-sim0278-entered-phase-ii-clinical-trial-stage</link>
      <guid isPermaLink="true">https://6ix.com/company/simcere-pharmaceutical-group-ltd/news/simceres-il-2-mutant-fusion-protein-sim0278-entered-phase-ii-clinical-trial-stage</guid>
      <pubDate>Mon, 10 Nov 2025 12:06:00 GMT</pubDate>
      <description>Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of moderate-to-severe atopic dermatitis (AD). The first dose was achieved in Hangzhou First People&apos;s Hospital.</description>
    </item>
    <item>
      <title>Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma</title>
      <link>https://6ix.com/company/simcere-pharmaceutical-group-ltd/news/simcere-zaiming-announces-first-patient-dosed-in-the-us-in-a-phase-1-trial-of-trispecific-antibody-sim0500-in-patients-with-relapsedrefractory-multiple-myeloma</link>
      <guid isPermaLink="true">https://6ix.com/company/simcere-pharmaceutical-group-ltd/news/simcere-zaiming-announces-first-patient-dosed-in-the-us-in-a-phase-1-trial-of-trispecific-antibody-sim0500-in-patients-with-relapsedrefractory-multiple-myeloma</guid>
      <pubDate>Thu, 19 Jun 2025 00:37:00 GMT</pubDate>
      <description>Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-101, NCT06375044) at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of SIM0500 in patients with relapsed/refractory multiple myeloma (RRMM).</description>
    </item>
  </channel>
</rss>